Peptide News Digest

Novo PIONEER TEENS Oral Semaglutide Pediatric T2D, Fractyl REMAIN-1 Gut Reset, Roche Q1 Obesity Pipeline, Foundayo Trailing Wegovy Pill

Novo's PIONEER TEENS pediatric T2D oral semaglutide positive; Fractyl REMAIN-1 gut-reset prevents post-GLP-1 weight regain; Roche projects $9B obesity pipeline peak sales.

10 stories · Covering clinical-trials, industry, regulatory, research

Editor's Note

The obesity peptide story keeps broadening. Novo Nordisk's PIONEER TEENS Phase 3a data positions oral semaglutide as the first oral GLP-1 for children and adolescents with type 2 diabetes — a meaningful pediatric milestone in a category that has so far centered on adult obesity. Fractyl Health's REMAIN-1 midpoint data, accepted for DDW 2026, captures the nascent 'post-GLP-1 maintenance' subcategory: a duodenal mucosal resurfacing 'gut reset' procedure cut weight regain by 40% in patients who discontinued tirzepatide. Roche's Q1 2026 earnings call projected $9 billion in peak sales from its obesity pipeline, with petrelintide and enicepatide Phase 2 data headed for ADA 2026 — underscoring how quickly second-tier players are mobilizing. Meanwhile, Foundayo's week-two prescription tracker came in at 3,707 scripts — well behind the Wegovy pill's ~18,000 trajectory at the same stage — and Lilly's stock paid for it. On the non-GLP-1 side, SVEDA launched a new peptide serum, Bicycle Therapeutics unveiled its ASCO 2026 Nuzefatide program, FDA awarded three National Priority Review Vouchers to psychedelic drug developers (part of the same program framework that accelerated Foundayo), and Regeneron's Otarmeni became the first gene therapy approved under that voucher system.

Clinical Trials

Novo Nordisk PIONEER TEENS Phase 3a Trial: Oral Semaglutide Shows Superior HbA1c Reduction in Children and Adolescents with Type 2 Diabetes

Novo Nordisk announced April 23 positive topline results from the PIONEER TEENS trial: a 52-week, randomized, double-blind, placebo-controlled Phase 3a study of oral semaglutide (3, 7, or 14 mg once daily) in 132 children and adolescents aged 10-17 with type 2 diabetes. Oral semaglutide reduced HbA1c by 0.83 percentage points more than placebo at 26 weeks with a well-tolerated safety profile. Pending regulatory approvals, it would be the first oral GLP-1 RA for this pediatric population. Novo expects to file for label expansion in the US and EU in H2 2026.

#novo-nordisk #oral-semaglutide #pioneer-teens #pediatric-diabetes #glp-1 #phase-3
Clinical Trials

Fractyl Health REMAIN-1 Midpoint Cohort Data: Revita Duodenal Mucosal Resurfacing Cuts Post-Tirzepatide Weight Regain by 40% — Accepted for DDW 2026

Fractyl Health's REMAIN-1 study — the first blinded, randomized, sham-controlled trial of an endoscopic 'gut reset' procedure — was accepted for presentation at DDW 2026. In 45 adults who had lost ≥15% body weight on tirzepatide and then discontinued, 29 received Revita duodenal mucosal resurfacing and 16 had a sham procedure. At 6 months post-discontinuation, Revita-treated patients regained 4.5% vs 7.5% for sham (P=0.07) — a 40% lower weight regain. Patients with more tissue resurfaced maintained >80% of pre-discontinuation weight loss. Topline pivotal-cohort data expected Q4 2026.

#fractyl-health #revita #duodenal-mucosal-resurfacing #remain-1 #glp-1-discontinuation #tirzepatide #ddw-2026
Industry

Roche Q1 2026 Earnings: Executives Project $9B Peak Sales for Obesity Pipeline, Petrelintide + Enicepatide Data Coming to ADA 2026

Roche reported Q1 2026 sales up 6% at constant exchange rates and used the earnings call to re-anchor its obesity strategy. Executives project $9 billion in peak annual sales from the emerging breast cancer pill plus four obesity candidates. Lead asset petrelintide (licensed from Zealand Pharma, ZUPREME-1 Phase 2 showed up to 10.7% weight loss with placebo-like tolerability) is positioned at a differentiated patient segment. CEO Schinecker said Roche is not investing in the first generation of obesity drugs, but the next — with petrelintide and CT-388 (enicepatide) data headed for ADA 2026.

#roche #q1-2026 #petrelintide #enicepatide #ct-388 #obesity-pipeline #amylin
Industry

Foundayo Week 2 IQVIA Tracker: 3,707 Prescriptions vs. Wegovy Pill's Comparable Week 18,410 — Lilly Stock Sags

Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.

#foundayo #orforglipron #eli-lilly #iqvia #wegovy-pill #prescription-tracker
Industry

SVEDA Launches Renewal Peptide Serum with Amino Acid and Bakuchiol Complex

Clean luxury skincare brand SVEDA launched its Renewal Peptide Serum ($124.99) on April 24. The formulation pairs caviar extract and hydrolyzed pearl (providing amino acids and trace minerals supporting collagen synthesis) with bakuchiol (a plant-derived retinol alternative), green tea hydrosol, Tsubaki seed oil, and grass-fed beef tallow. The launch lands in a broader consumer-peptide boom — 'peptide therapy' search interest is up 281% YoY on Google, 459% on TikTok, and 412% on Instagram as cosmetic brands rush to capture the mainstreaming trend.

#sveda #cosmetic-peptide #bakuchiol #collagen #skincare-launch #peptide-therapy-trend
Clinical Trials

Bicycle Therapeutics Announces ASCO 2026 Oral and Poster Program for Nuzefatide Pevedotin (BT5528) Across Multiple Tumor Types

Bicycle Therapeutics announced April 21 its program for the 2026 ASCO Annual Meeting (May 29-June 2 in Chicago), with an oral presentation and five poster abstracts on nuzefatide pevedotin — its EphA2-targeting bicyclic peptide drug conjugate. Key data from Phase 1/2 include the recently disclosed 40% ORR in checkpoint-refractory urothelial cancer, expanded head-and-neck squamous cell carcinoma preclinical data, and the selected 8mg/m² Q2W dose for the Phase 2 recurrent pancreatic cancer trial. The program solidifies Nuzefatide's positioning as a leading bicyclic peptide drug conjugate in oncology.

#bicycle-therapeutics #nuzefatide-pevedotin #bt5528 #epha2 #bicyclic-peptide #asco-2026
Regulatory

FDA Awards Three National Priority Review Vouchers to Psychedelic Drug Developers — Same Program That Accelerated Foundayo

On April 24 the FDA awarded three National Priority Review Vouchers to companies developing psychedelic therapies: Compass Pathways (psilocybin for treatment-resistant depression), Otsuka Pharmaceutical, and the non-profit Usona Institute (methylone for PTSD). This is the same voucher program that enabled Lilly's Foundayo (orforglipron) to be reviewed in 50 days. The program's expansion into psychedelics signals FDA's continued willingness to use priority vouchers aggressively for novel mental health and metabolic candidates — with peptide developers watching closely ahead of the July PCAC meeting.

#fda #national-priority-voucher #psychedelics #compass-pathways #otsuka #usona
Regulatory

FDA Approves Regeneron's Otarmeni Gene Therapy for Inherited Hearing Loss — First Gene Therapy Under National Priority Voucher

The FDA granted accelerated approval April 23 for Regeneron's Otarmeni (lunsotogene parvec-cwha), a gene therapy for certain forms of genetic hearing loss. Otarmeni is the first gene therapy cleared under the FDA's National Priority Voucher program and will be offered to eligible patients at no cost. The approval validates the priority voucher pathway's applicability beyond GLP-1 drugs and establishes regulatory precedent that peptide developers may invoke if the July PCAC meeting produces favorable reclassification recommendations.

#fda #regeneron #otarmeni #gene-therapy #national-priority-voucher #hearing-loss
Industry

Amgen MariTide Positioning Pre-Q1 Earnings: Monthly GLP-1/GIPR Antagonist Obesity Candidate in Six Global Phase 3 Trials

Ahead of Amgen's April 30 Q1 2026 earnings release, analyst coverage highlighted MariTide as the company's most closely-watched pipeline asset. The bispecific GLP-1 RA / GIPR antagonist delivered up to 20% weight loss at 52 weeks in Phase 2 and is now enrolled across six global Phase 3 trials — with monthly, bi-monthly, and potentially quarterly dosing as its primary commercial differentiator against weekly GLP-1s. Amgen recorded $35.1 billion in 2025 product sales (+10%), and MariTide headline data from the Phase 3 program is expected to begin reading out in 2027.

#amgen #maritide #glp-1-gipr #monthly-dosing #phase-3 #q1-earnings
Research

Scorpion-Inspired Antimicrobial Peptide Mu-17 Shows Dual Breast Cancer Activity and Broad-Spectrum Antibacterial Effect

A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.

#antimicrobial-peptide #scorpion-venom #mu-17 #breast-cancer #leucine-zipper #amp